Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

News headlines Vertex Pharmaceuticals is experiencing notable growth driven by its expanding pipeline and strong market interest, particularly in gene therapies. Recent clinical data and regulatory ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Broad form insurance provides coverage for uncommon or higher-risk events, which is why it ...